Fibrocell Science, Inc.'s LAVIV™ Recognized in the Prestigious Wall Street Journal Technology Innova
Fibrocell Science, Inc.'s LAVIV™ Recognized in the Prestigious Wall Street Journal Technology Innovation Awards
EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. announced that LAVIV™ (azficel-T) was recognized in this year's Wall Street Journal Technology Innovation Awards. LAVIV, the first and only personalized cell treatment approved by the FDA to improve the appearance of nasolabial folds or "smile line" wrinkles, was named a runner-up in the Medicine and Biotech category. The Awards recognize companies and products that have the potential to widely impact their industries and make a difference in people's lives.
"We are extremely pleased that The Wall Street Journal recognized LAVIV as part of its Technology Innovation Awards," said David Pernock, Chairman and CEO of Fibrocell Science, Inc. "This award highlights the innovative technology behind LAVIV, which isolates, purifies and multiplies a patient's own collagen-producing fibroblast cells. We look forward to advancing our fibroblast platform with new indications for unmet medical needs beyond aesthetics."
The Wall Street Journal received 536 applications from more than two dozen countries. A team of Journal editors and reporters reviewed the entries and forwarded 172 to an independent panel of judges from venture-capital firms, universities and companies. From that pool, the judges chose a total of 37 winners and runners-up in 18 categories.
About The Wall Street Journal Technology Innovation Awards
In its 12th year, The Wall Street Journal Technology Innovation Awards recognize technological advances that break with conventional processes in specific fields, offer more than marginal improvements compared to existing technology and those that will have a wide impact on the industry or field.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science, Inc. is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
About LAVIV™ (azficel-T)
LAVIV was approved by the FDA on June 21, 2011 for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles in adults and is the first and only personalized cell treatment approved by the FDA for aesthetic use. The safety and efficacy of LAVIV for areas other than nasolabial folds have not been established; nor has the efficacy of LAVIV beyond six months been established.
LAVIV is now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science, Inc. on the treatment process. A list of trained and certified physicians is available at www.mylaviv.com and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.
Important Safety Information About LAVIV™ (azficel-T)
LAVIV is made especially for you from your own skin cells. Using someone else's cells can cause a serious reaction. Do not let anyone else use your LAVIV. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct. Your healthcare provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or COUMADIN® (warfarin sodium), keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. Tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.
The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment. There are additional adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these adverse reactions. For more information about LAVIV, please see accompanying full Prescribing Information or visit www.mylaviv.com.
Media
Marina Maher Communications LLC
Heather Adamson, 212-485-6806
hadamson@mahercomm.com
or
Investors
ICR
Sherry Bertner, 646-277-1247
Sherry.Bertner@icrinc.com
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS:
The article Fibrocell Science, Inc.'s LAVIV™ Recognized in the Prestigious Wall Street Journal Technology Innovation Awards originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
